(E)-isopropyl 1-propenyl sulfone | 69113-44-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: (E)-isopropyl 1-propenyl sulfone
• 英文别名: 1t-(propane-2-sulfonyl)-propene；trans-1-Propenylisopropylsulfon；(E)-1-propan-2-ylsulfonylprop-1-ene
• CAS: 69113-44-6
• 化学式: C₆H₁₂O₂S
• 分子量: 148.226
• InChiKey: KOVVPDULUFDMSM-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-isopropyl 1-propenyl sulfone 在 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 生成 (Z)-isopropyl 1-propenyl sulfone
  参考文献：
  名称：

  Svata,V. et al., Collection of Czechoslovak Chemical Communications, 1978, vol. 43, p. 2619 - 2634

  摘要：

  DOI：
• 作为产物：
  描述：

  烯丙基异丙基硫醚 生成 (E)-isopropyl 1-propenyl sulfone
  参考文献：
  名称：

  Svata,V. et al., Collection of Czechoslovak Chemical Communications, 1978, vol. 43, p. 2619 - 2634

  摘要：

  DOI：

文献信息

• Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase
  申请人：REDX PHARMA PLC

  公开号：US20170129897A1

  公开（公告）日：2017-05-11

  This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
• METHOD FOR SCREENING INHIBITORS OF RAS
  申请人：Araxes Pharma LLC

  公开号：US20170131278A1

  公开（公告）日：2017-05-11

  Provided herein are compositions, reactions mixtures, mutant Ras proteins, kits, substrates, and systems for selecting a Ras antagonist, as well as methods of using the same.
• THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：The Regents of the University of Michigan

  公开号：US20170247391A1

  公开（公告）日：2017-08-31

  The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.
• METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS
  申请人：Kura Oncology, Inc.

  公开号：US20180105531A1

  公开（公告）日：2018-04-19

  The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
• US9810690B2
  申请人：——

  公开号：US9810690B2

  公开（公告）日：2017-11-07